NSETrading Window26 Jun 2026 · 26 Jun 2026, 03:48 pm
Trading Window
Senores Pharmaceuticals Limited · SENORES
✦ AI SummaryRegulatory
Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of unaudited financial results for the quarter ending June 30, 2026.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk3/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Attachments (1)
📄pdf
Download →
SENORES_26062026154814_Intimationregardingclosureoftradingwindowsigned.pdf
View document text
Date: June 26, 2026
To, To,
Sr. General Manager Sr. General Manager
Listing Department Listing Department
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G
Dalal Street Bandra Kurla Complex
Mumbai – 400001 Bandra (E), Mumbai – 400 051
BSE Scrip Code: 544319 NSE Symbol: SENORES
Dear Sir/Madam,
Subject: Intimation of Trading Window Closure
Pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading)
Regulations, 2015 (“SEBI PIT Regulations”) as amended from time to time and Company's Code of
Conduct (“Code”) for prevention of insider trading, the trading window, for trading in the securities of
the Company by the Directors, Promoters, Designated Persons and their immediate relatives, shall
remain closed from July 01, 2026 till 48 hours after announcement / declaration of Unaudited Financial
Results for quarter ending on June 30, 2026.
In view of the above, all the Directors, Promoters, Designated Persons and their immediate relatives are
advised not to trade in the securities of the Company during the aforesaid period of closure of trading
window.
The date of Board Meeting for approving the Unaudited Financial Results for quarter ending on June 30,
2026, will be intimated separately in due course.
You are requested to take the same on record and acknowledge the receipt of the same.
Thanking you.
For Senores Pharmaceuticals Limited
Deval Rajnikant Shah
Whole Time Director & CFO
DIN: 00332722
Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India
P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263